Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects

AIMS: Selexipag is a prostacyclin receptor agonist approved for the treatment of pulmonary arterial hypertension. Cytochrome P450 (CYP) 2C8 is involved in the metabolism of selexipag and its active metabolite, ACT‐333679. This study evaluated the interaction of selexipag and clopidogrel, a CYP2C8 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Axelsen, Lene Nygaard, Poggesi, Italo, Rasschaert, Freya, Perez Ruixo, Juan Jose, Bruderer, Shirin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328278/
https://www.ncbi.nlm.nih.gov/pubmed/32415684
http://dx.doi.org/10.1111/bcp.14365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328278/
https://www.ncbi.nlm.nih.gov/pubmed/32415684
http://dx.doi.org/10.1111/bcp.14365

Ejemplares similares